Medigen Vaccine Biologics Corp
In collaboration with the US NIH/NIAID and their solid technology based on culmination of over 15 years of research on coronavirus, MVC develops SARS-CoV-2 vaccine with genetically modified Spike protein as antigen, making it more stable and highly immunogenic. MVC is conducting animal studies and strives to enter human clinical trials in full speed.